Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.36 |
| ▸ | FDPS | P14324 | 3/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463961 | 0.80 | DNM1 (0.34) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL3306948 | 0.71 | LMNA (0.39) | LMNALCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL28306844 | 0.71 | FDPS (0.44) | LMNALCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL3303049 | 0.71 | LMNA (0.39) | LMNALCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL17787405 | 0.71 | TSHR (0.50) | ZDHHC7LMNALCKPPARDZDHHC20 | |
| SCHEMBL22698780 | 0.71 | TSHR (0.50) | ZDHHC7LMNALCKPPARDZDHHC20 | |
| SCHEMBL14639891 | 0.71 | TSHR (0.50) | ZDHHC7LMNALCKPPARDZDHHC20 | |
| SCHEMBL14641771 | 0.71 | TSHR (0.50) | ZDHHC7LMNALCKPPARDZDHHC20 | |
| SCHEMBL19069927 | 0.71 | TSHR (0.50) | ZDHHC7LMNALCKPPARDZDHHC20 | |
| SCHEMBL8272324 | 0.71 | TSHR (0.50) | ZDHHC7LMNALCKPPARDZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241224-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | SANEGENE BIO USA INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241224-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | PARP1, PARP2, CD38 | ZDHHC7 1880/4885LMNA 180/4885LCK 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.